Futibatinib, ESR1, & GPRC5D
Oct 06, 2022•16 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
A new FGFR inhibitor, futibatinib, is approved.
Is ESR1 mutation monitoring the next thing in HR+ metastatic breast cancer? The PADA-1 trial offers insight.
What the heck is GPRC5D (rhymes with CAR-T)?
PADA-1: https://doi.org/10.1016/S1470-2045(22)00555-1
GPRC5D CAR-T in Myeloma: https://www.nejm.org/doi/full/10.1056/NEJMoa2209900
For the best experience, listen in Metacast app for iOS or Android